Antihypertensive Agents and Rhabdomyolysis Risk in Black Patients
The available evidence does not identify any antihypertensive medication class that causes rhabdomyolysis specifically in Black patients; however, thiazide diuretics (particularly when combined with statins) and spironolactone (when combined with fibrates) have been associated with rhabdomyolysis risk in general populations, and these agents are commonly prescribed as first-line therapy in Black patients.
Evidence-Based Risk Associations
Thiazide Diuretics Combined with Statins
Hydrochlorothiazide combined with simvastatin has been documented to precipitate severe rhabdomyolysis, particularly in elderly patients with multiple cardiovascular risk factors, through mechanisms involving volume depletion and hypokalemia that potentiate statin myotoxicity 1.
The combination of simvastatin with mefruside (a thiazide-like diuretic) generated a signal for rhabdomyolysis in Japanese pharmacovigilance data, suggesting drug-drug interaction potential 2.
Thiazide-induced hypokalemia independently predisposes to muscle injury and can synergize with statin-induced myotoxicity, especially when combined with SGLT2 inhibitors that further exacerbate volume depletion 1.
Spironolactone Combined with Fibrates
Bezafibrate combined with spironolactone was detected as a signal for rhabdomyolysis in the Japanese Adverse Drug Event Report database analysis 2.
Spironolactone use in the context of licorice-containing herbal medicines has been associated with pseudoaldosteronism and rhabdomyolysis, particularly in elderly women with hypertension 3.
Other Antihypertensive Combinations
ACE inhibitors (temocapril) combined with fibrates (bezafibrate or fluvastatin) generated rhabdomyolysis signals in pharmacovigilance data 2.
Losartan combined with bezafibrate and metoprolol combined with bezafibrate were also flagged as potential two-drug combinations associated with rhabdomyolysis risk 2.
Clinical Context for Black Patients
Why This Matters for Black Patients
Thiazide diuretics and calcium channel blockers are the recommended first-line antihypertensive agents for Black patients according to ACC/AHA guidelines, making thiazide exposure nearly universal in this population 4, 5.
Most Black patients require two or more antihypertensive medications to achieve blood pressure targets below 130/80 mmHg, increasing polypharmacy exposure 5, 6, 7.
Chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 25-50 mg daily are specifically recommended as preferred initial therapy in Black patients, and these are the same thiazide agents implicated in rhabdomyolysis when combined with statins 5, 6, 7.
Mechanistic Considerations
Thiazide diuretics cause dose-related hypokalemia and volume depletion, both of which are independent risk factors for rhabdomyolysis and can amplify statin myotoxicity 1.
Statins themselves carry an elevated risk of rhabdomyolysis (adjusted OR 1.70,95% CI 1.68-1.73), and this risk is further increased when combined with medications that cause electrolyte disturbances 8.
The myoglobin-to-creatine kinase ratio ≥0.48 at admission identifies 89% of patients who will develop acute kidney injury from rhabdomyolysis, providing an early risk stratification tool 9.
Practical Clinical Algorithm
Risk Stratification Before Prescribing
Identify patients on statin therapy (especially simvastatin, lovastatin, or atorvastatin) before initiating thiazide diuretics 4, 1.
Check baseline potassium, creatine kinase, and renal function in all Black patients starting combination antihypertensive therapy with thiazides 1.
Avoid combining thiazide diuretics with fibrates (bezafibrate, fenofibrate) unless absolutely necessary, and monitor closely if unavoidable 2.
Monitoring During Treatment
Monitor serum potassium every 2-4 weeks after initiating thiazide therapy, especially in patients on concurrent statins or SGLT2 inhibitors 1.
Educate patients to report muscle pain, weakness, dark urine, or unexplained fatigue immediately, as these are early signs of rhabdomyolysis 1, 10.
Measure creatine kinase and myoglobin if muscle symptoms develop; a myoglobin-to-CK ratio ≥0.48 or myoglobin ≥4489 ng/mL indicates high risk for acute kidney injury 9.
Medication Selection to Minimize Risk
Prefer calcium channel blockers (amlodipine 5-10 mg daily) over thiazides as initial monotherapy in Black patients already on statin therapy, as CCBs do not cause electrolyte disturbances 5, 6.
If thiazide diuretics are necessary in statin users, choose chlorthalidone at the lowest effective dose (12.5 mg daily) and ensure aggressive potassium monitoring 5, 6.
Avoid spironolactone in patients on fibrate therapy due to documented drug-drug interaction signals 2.
Important Caveats
No race-specific data exist demonstrating differential rhabdomyolysis risk from antihypertensives in Black versus non-Black patients; the concern arises from the preferential use of thiazides in this population combined with general population drug interaction data 2, 1.
The absolute risk of rhabdomyolysis from antihypertensive monotherapy is extremely low; the documented cases involve polypharmacy with statins, fibrates, or other myotoxic agents 2, 1, 8.
Elderly patients with diabetes, vascular disease, and multiple medications represent the highest-risk subgroup for thiazide-statin interactions, regardless of race 1.